InDevR Launches 5’CapQ for Rapid Critical Quality Attribute Determination of mRNA-Based Vaccines
New Kit Lets Vaccine Manufacturers Test 5′ Capping Efficiency at the Bench, With Answers in Less Than Two Hours InDevR Inc., a leader in analytical...
InDevR and Sino Biological Team Up to Deliver Multiplexed Analytical Solutions for mRNA Vaccine and Cell & Gene Therapy
Partnership addresses biopharmaceutical industry’s urgent need for improved in-process and QC testing tools for these rapidly evolving application fields InDevR, Inc., a leader in analytical...
AmplifyBio and RNAV8 Bio Announce Strategic Partnership to Support mRNA Therapeutic Developers from Sequence Design to GMP Manufacture
AmplifyBio, a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) focused on differentiating services that cover target optimization, preclinical safety studies, and...
Repair Biotechnologies Demonstrates Rapid Reversal of Atherosclerosis in Mouse Models
Following favorable FDA feedback for the treatment of liver disease, the company is preparing further pre-IND meetings with the FDA for the treatment of atherosclerosis...
Phoreus Biotech Appoints David Schaefer as CEO to Lead Development of Innovative Drug Delivery Nanocarriers
Phoreus Biotech, an innovator in peptide nanocarriers for drug and vaccine delivery, is proud to announce the appointment of David Schaefer as its new Chief...
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
The Enterprise Solutions Hub in the Philippines will support the Asia Pacific region and complements Moderna's Enterprise Solutions Hubs in Warsaw, Poland, and Atlanta, U.S.The...
Moderna Announces Clinical and Program Updates at 4th Vaccines Day
Next-generation, refrigerator-stable COVID-19 vaccine candidate, mRNA-1283, has dosed first participant in its Phase 3 trialCompany expects to file for approval of its investigational RSV vaccine...
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanomaCAMBRIDGE, MA and RAHWAY,...
Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that...
Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
Expansion includes new West Coast offices in South San Francisco, California and Seattle, WashingtonNew offices complement existing locations in Cambridge, MA; Norwood, MA; Atlanta, GA;...